Allergic diseases such as asthma and rhinitis, as well the early phase of atopic dermatitis, are characterized by a Th2-skewed immune environment. Th2-type cytokines are upregulated in allergic inflammation, whereas there is downregulation of the Th1-type immune response and related cytokines, such as interferon-γ (IFN-γ). The latter is a strong inducer of indoleamine 2,3-dioxygenase-1 (IDO-1), which degrades the essential amino acid tryptophan, as part of an antiproliferative strategy of immunocompetent cells to halt the growth of infected and malignant cells, and also of T cells - an immunoregulatory intervention to avoid overactivation of the immune system. Raised serum tryptophan concentrations have been reported in patients with pollen allergy compared to healthy blood donors. Moreover, higher baseline tryptophan concentrations have been associated with a poor response to specific immunotherapy. It has been shown that the increase in tryptophan concentrations in patients with pollen allergy only exists outside the pollen season, and not during the season. Interestingly, there is only a minor alteration of the kynurenine to tryptophan ratio (Kyn/Trp, an index of tryptophan breakdown). The reason for the higher tryptophan concentrations in patients with pollen allergy outside the season remains a matter of discussion. To this regard, the specific interaction of nitric oxide (NO∙) with the tryptophan-degrading enzyme IDO-1 could be important, because an enhanced formation of NO∙ has been reported in patients with asthma and allergic rhinitis. Importantly, NO∙ suppresses the activity of the heme enzyme IDO-1, which could explain the higher tryptophan levels. Thus, inhibitors of inducible NO∙ synthase should be reconsidered as candidates for antiallergic therapy out of season that may abrogate the arrest of IDO-1 by decreasing the production of NO∙. Considering its association with the pathophysiology of atopic disease, tryptophan metabolism may play a relevant role in the pathophysiology of allergic disorders.

Keywords:
Kynurenine to tryptophan ratio, Neopterin, Allergy, Atopy, Indoleamine 2,3-dioxygenase-1, Interferon-γ, Nitric oxide, Th2-type immunity, Tryptophan 2,3-dioxygenase
1.
Isolauri E, Huurre A, Salminen S, Impivaara O: The allergy epidemic extends beyond the past few decades. Clin Exp Allergy 2004;34:1007-1010.
2.
Prescott SL: Allergic disease: understanding how in utero events set the scene. Proc Nutr Soc 2010;69:366-372.
3.
Strachan DP: Hay fever, hygiene, and household size. Brit Med J 1989;299:1259-1260.
4.
Krämer U, Heinrich J, Wjst M, Wichmann HE: Age of entry to day nursery and allergy in later childhood. Lancet 1999;353:450-454.
5.
Yazdanbakhsh M, Kremsner PG, van Ree R: Allergy, parasites, and the hygiene hypothesis. Science 2002;296:490-494.
6.
Liu AH, Murphy JR: Hygiene hypothesis: fact or fiction? J Allergy Clin Immunol 2003;111:471-478.
7.
Fuchs D: Antioxidant intake and allergic disease. Clin Exp Allergy 2012;42:1420-1422.
8.
Murr C, Schroecksnadel K, Winkler C, Ledochowski M, Fuchs D: Antioxidants may increase the probability of developing allergic diseases and asthma. Med Hypotheses 2005;64:973-977.
9.
Gostner J, Ciardi C, Becker K, Fuchs D, Sucher R: Immunoregulatory impact of food antioxidants. Curr Pharm Des 2014;20:840-849.
10.
Kositz C, Schroecksnadel K, Grander G, Schennach H, Kofler H, Fuchs D: Serum tryptophan concentration in patients predicts outcome of specific immunotherapy with pollen extracts. Int Arch Allergy Immunol 2008;147:35-40.
11.
Widner B, Werner ER, Schennach H, Wachter H, Fuchs D: Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem 1997;43:2424-2426.
12.
Schroecksnadel K, Wirleitner B, Winkler C, Fuchs D: Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 2006;364:82-90.
13.
Chen Y, Guillemin GJ: Kynurenine pathway metabolites in humans: disease and healthy States. Int J Tryptophan Res 2009;2:1-19.
14.
Knox WE: The regulation of tryptophan pyrrolase activity by tryptophan. Adv Enzyme Regul 1966;4:287-297.
15.
Werner ER, Hirsch-Kauffmann M, Fuchs D, Hausen A, Reibnegger G, Schweiger M, Wachter H: Interferon-γ-induced degradation of tryptophan by human cells in vitro. Biol Chem Hoppe Seyler 1987;368:1407-1412.
16.
Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, Dilling LA, Elia J, Kruesi MJ, Lackner A: Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992;115:1249-1273.
17.
Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith Q: Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 1991;56:2007-2017.
18.
Klein C, Patte-Mensah C, Taleb O, Bourguignon JJ, Schmitt M, Bihel, F, Maitre M, Mensah-Nyagan AG: The neuroprotector kynurenic acid increases neuronal cell survival through neprilysin induction. Neuropharmacology 2013;70:254-260.
19.
Sas K, Robotka H, Toldi J, Vécsei L: Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci 2007;257:221-239.
20.
Widner B, Laich A, Sperner-Unterweger B, Ledochowski M, Fuchs D: Neopterin production tryptophan degradation and mental depression: what is the link? Brain Behav Immun 2002;16:590-595.
21.
Schröcksnadel H, Baier-Bitterlich G, Dapunt O, Wachter H, Fuchs D: Decreased plasma tryptophan in pregnancy. Obstet Gynecol 1996;88:47-50.
22.
Murr C, Widner B, Wirleitner B, Fuchs D: Neopterin as a marker for immune system activation. Curr Drug Metabol 2002;3:175-187.
23.
Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL: Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998;281:1191-1193.
24.
Mellor AL, Munn DH: IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4:762-774.
25.
Widner B, Ledochowski M, Fuchs D: Interferon-γ-induced tryptophan degradation: neuropsychiatric and immunological consequences. Curr Drug Metabol 2000;1:193-204.
26.
Raitala A, Karjalainen J, Oja SS, Kosunen TU, Hurme M: Indoleamine 2,3-dioxygenase (IDO) activity is lower in atopic than in non-atopic individuals and is enhanced by environmental factors protecting from atopy. Mol Immunol 2006;43:1054-1056.
27.
Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D: Tryptophan degradation and immune activation in Alzheimer's disease. J Neural Transm (Vienna) 2000;107:343-353.
28.
Nathan CF, Murray HW, Wiebe ME, Rubin BY: Identification of interferon-γ as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983;158:670-689.
29.
Werner ER, Werner-Felmayer G, Fuchs D, Hausen A, Reibnegger R, Yim JJ, Wachter H: Biochemistry and function of pteridine synthesis in human and murine macrophages. Pathobiology 1991;59:276-279.
30.
Romagnani S: Regulation of the T cell response. Clin Exp Allergy 2006;36:1357-1366.
31.
Zaknun D, Schroecksnadel S, Kurz K, Fuchs D: Potential role of antioxidant food supplements, preservatives and colorants in the pathogenesis of allergy and asthma. Int Arch Allergy Immunol 2012;157:113-124.
32.
Poljsak B, Milisav I: The neglected significance of ‘antioxidative stress'. Oxid Med Cell Longev 2012;2012:480895.
33.
Zhou L, Chong MM, Littman DR: Plasticity of CD4+ T cell lineage differentiation. Immunity 2009;30:646-655.
34.
Romagnani S: Immunologic influences on allergy and the TH1/TH2 balance. J Allergy Clin Immunol 2004;113:395-400.
35.
Barth H, Berg PA, Klein R: Methods for the in vitro determination of an individual disposition towards TH1- or TH2-reactivity by the application of appropriate stimulatory antigens. Clin Exp Immunol 2003;134:78-85.
36.
Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-1061.
37.
Fallarino F, Grohmann U, Puccetti P: Indoleamine 2,3-dioxygenase: from catalyst to signaling function. Eur J Immunol 2012;42:1932-1937.
38.
van Voorhis M, Fechner JH, Zhang X, Mezrich JD: The aryl hydrocarbon receptor: a novel target for immunomodulation in organ transplantation. Transplantation 2013;95:983-990.
39.
Fuchs D, Weiss G, Reibnegger G, Wachter H: The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious and malignant diseases. Crit Rev Clin Lab Sci 1992;29:307-341.
40.
Weiss G, Murr C, Zoller H, Haun M, Widner B, Ludescher C, Fuchs D: Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells. Clin Exp Immunol 1999;116:435-440.
41.
Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H: Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today 1988;9:150-155.
42.
Fuchs D, Avanzas P, Arroyo-Espliguero R, Jenny M, Consuegra Sanchez L, Kaski JC: The role of neopterin in atherogenesis and cardiovascular risk stratification. Curr Med Chem 2009;16:4644-4653.
43.
De Rosa S, Cirillo P, Pacileo M, Petrillo G, D'Ascoli GL, Maresca F, Ziviello F, Chiariello M: Neopterin: from forgotten biomarker to leading actor in cardiovascular pathophysiology. Curr Vasc Pharmacol 2011;9:188-199.
44.
Pedersen ER, Midttun Ø, Ueland PM, Schartum-Hansen H, Seifert R, Igland J, Nordrehaug JE, Ebbing M, Svingen G, Bleie Ø, Berge R, Nygård O: Systemic markers of interferon-γ-mediated immune activation and long-term prognosis in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2011;31:698-704.
45.
Fuchs D, Möller AA, Reibnegger G, Stöckle E, Werner ER, Wachter H: Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr 1990;3:873-876.
46.
Nathan CF: Peroxide and pteridine: a hypothesis on the regulation of macrophage antimicrobial activity by interferon gamma. Interferon 1986;7:125-143.
47.
Murr C, Schroecksnadel K, Winklhofer-Roob BM, Mangge H, Böhm BO, Winkelmann BR, Maerz W, Fuchs D: Inverse association between serum concentrations of neopterin and antioxidants in patients with and without angiographic coronary artery disease. Atherosclerosis 2009;202:543-549.
48.
Holt PG, Macaubas C, Stumbles PA, Sly PD: The role of allergy in the development of asthma. Nature 1999;402(6760 suppl):B12-B17.
49.
Ciprandi G, Tosca M, Fuchs D: Nitric oxide metabolites in allergic rhinitis: the effect of pollen allergen exposure. Allergol Immunopathol 2011;39:326-329.
50.
Brown JM, Wilson TM, Metcalfe DD: The mast cell and allergic diseases: role in pathogenesis and implications for therapy. Clin Exp Allergy 2008;38:4-18.
51.
van der Sluijs KF, van de Pol MA, Kulik W, Dijkhuis A, Smids BS, van Eijk HW, Karlas JA, Molenkamp R, Wolthers KC, Johnston SL, van der Zee JS, Sterk PJ, Lutter R; RESOLVE Research Team: Systemic tryptophan and kynurenine catabolite levels relate to severity of rhinovirus-induced asthma exacerbation: a prospective study with a parallel-group design. Thorax 2013;68:1122-1130.
52.
von Bubnoff D, Bieber T: The indoleamine 2,3-dioxygenase (IDO) pathway controls allergy. Allergy 2012;67:718-725.
53.
Thomas PS: Tumour necrosis factor-α: the role of this multifunctional cytokine in asthma. Immunol Cell Biol 2001;79:132-140.
54.
Calderón MA, Devalia JL, Prior AJ, Sapsford RJ, Davies RJ: A comparison of cytokine release from epithelial cells cultured from nasal biopsy specimens of atopic patients with and without rhinitis and nonatopic subjects without rhinitis. J Allergy Clin Immunol 1997;99:65-76.
55.
Cembrzynska-Nowak M, Szklarz E, Inglot AD, Teodorczyk-Injeyan JA: Elevated release of tumor necrosis factor-α and interferon-γ by bronchoalveolar leukocytes from patients with bronchial asthma. Am Rev Respir Dis 1993;147:291-295.
56.
Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H: Tumour necrosis factor-α and lipopolysaccharide enhance interferon-induced tryptophan degradation and pteridine synthesis in human cells. Biol Chem Hoppe Seyler 1989;370:1063-1069.
57.
Weiss G, Murr C, Zoller H, Haun M, Widner B, Ludescher C, Fuchs D: Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells. Clin Exp Immunol 1999;116:435-440.
58.
Schroecksnadel K, Winkler C, Wirleitner B, Schennach H, Fuchs D: Aspirin down-regulates tryptophan degradation in stimulated human peripheral blood mononuclear cells in vitro. Clin Exp Immunol 2005;140:41-45.
59.
Kuo CH, Kuo HF, Huang CH, Yang SN, Lee MS, Hung CH: Early life exposure to antibiotics and the risk of childhood allergic diseases: an update from the perspective of the hygiene hypothesis. J Microbiol Immunol Infect 2013;46:320-329.
60.
Saporta D: Efficacy of sublingual immunotherapy versus subcutaneous injection immunotherapy in allergic patients. J Environ Public Health 2012;2012:492405.
61.
Mungan D, Misirligil Z, Gürbüz L: Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma - a placebo controlled study. Ann Allergy Asthma Immunol 1999;82:485-490.
62.
André C, Vatrinet C, Galvain S, Carat F, Sicard H: Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000;121:229-234.
63.
Kofler H, Kurz K, Grander G, Fuchs D: Specific immunotherapy normalizes tryptophan concentrations in patients with allergic rhinitis. Int Arch Allergy Immunol 2012;159:416-421.
64.
Ciprandi G, De Amici M, Tosca M, Fuchs D: Tryptophan metabolism in allergic rhinitis: the effect of pollen allergen exposure. Hum Immunol 2010;71:911-915.
65.
von Bubnoff D, Fimmers R, Bogdanow M, Matz H, Koch S, Bieber T: Asymptomatic atopy is associated with increased indoleamine 2,3-dioxygenase activity and interleukin-10 production during seasonal allergen exposure. Clin Exp Allergy 2004;34:1056-1063.
66.
Thomas SR, Terentis AC, Cai H, Takikawa O, Levina A, Lay PA, Freewan M, Stocker R: Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide. J Biol Chem 2007;282:23778-23787.
67.
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al: Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 update. Allergy 2008;63(suppl 86):8-160.
68.
Ciprandi G, De Amici M, Tosca M, Fuchs D, Marseglia G: Serotonin in allergic rhinitis: a role for behavioural symptoms. Iran J Allergy Asthma Immunol 2011;10:183-188.
69.
Juniper EF, Guyatt GH: Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21:77-83.
70.
Boyer EW, Shannon M: The serotonin syndrome. N Engl J Med 2005:352:1112-1120.
71.
Ciprandi G, Fuchs D: Tryptophan, neopterin, and nitrite in allergy. Allergy 2013;67:1083.
72.
Stewart L, Katial RK: Exhaled nitric oxide. Immunol Allergy Clin North Am 2012;32:347-362.
73.
Henriksen AH, Sue-Chu M, Holmen TL, Langhammer A, Bjermer L: Exhaled and nasal NO levels in allergic rhinitis: relation to sensitization, pollen season and bronchial hyperresponsiveness. Eur Respir J 1999;13:301-306.
74.
Ciebiada M, Cichocki P, Kasztalska K, Majewski S, Gorska-Ciebiada M, Gorski P: Orally exhaled nitric oxide in patients with seasonal allergic rhinitis during natural pollen season. Am J Rhinol Allergy 2012;26:e32-e36.
75.
Nadif R, Rava M, Decoster B, Huyvaert H, Le Moual N, Bousquet J, Siroux V, Varraso R, Pin I, Zerimech F, Matran R: Exhaled nitric oxide, nitrite/nitrate levels, allergy, rhinitis and asthma in the EGEA study. Eur Respir J 2014;44:351-360.
76.
Unal M, Eskandari HG, Erçetin N, Doğruer ZN, Pata YS: Serum nitrite/nitrate and arginase levels in patients with allergic rhinitis. ORL J Otorhinolaryngol Relat Spec 2007;69:113-115.
77.
Samelson-Jones BJ, Yeh SR: Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry 2006;45:8527-8538.
78.
Hesslinger C, Strub A, Boer R, Ulrich WR, Lehner MD, Braun C: Inhibition of inducible nitric oxide synthase in respiratory diseases. Biochem Soc Trans 2009;37:886-891.
79.
Werner ER, Werner-Felmayer G, Fuchs D, Hausen A, Reibnegger G, Yim JJ, Pfleiderer W, Wachter H: Tetrahydrobiopterin biosynthetic activities in human macrophages, fibroblasts, THP-1 and T 24 cells. GTP-cyclohydrolase I is stimulated by interferon-γ, 6-pyruvoyl tetrahydropterin synthase and sepiapterin reductase are constitutively present. J Biol Chem 1990;265:3189-3192.
80.
Andrew PJ, Mayer B: Enzymatic function of nitric oxide synthases. Cardiovasc Res 1999;43:521-531.
81.
Villanueva C, Giulivi C: Subcellular and cellular locations of nitric oxide synthase isoforms as determinants of health and disease. Free Radic Biol Med 2010;49:307-316.
82.
Schroecksnadel S, Jenny M, Kurz K, Klein A, Ledochowski M, Ueberall F, Fuchs D: LPS-induced NF-κB expression in THP-1Blue cells correlates with neopterin production and activity of indoleamine 2,3-dioxygenase. Biochem Biophys Res Com 2010;399:642-646.
83.
Wink DA, Hines HB, Cheng RY, Switzer CH, Flores-Santana W, Vitek MP, Ridnour LA, Colton CA: Nitric oxide and redox mechanisms in the immune response. J Leukoc Biol 2011;89:873-891.
84.
Bowler RP, Crapo JD: Oxidative stress in allergic respiratory diseases. J Allergy Clin Immunol 2002;110:349-356.
85.
Aggarwal BB: Nuclear factor-κB: the enemy within. Cancer Cell 2004;6:203-208.
86.
Kuzkaya N, Weissmann N, Harrison DG, Dikalov S: Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 2003;278:22546-22554.
87.
Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C: Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. J Am Med Assoc 2007;297:842-857.
88.
Winkler C, Wirleitner B, Schroecksnadel K, Schennach H, Fuchs D: In vitro effects of beet root juice on stimulated and unstimulated peripheral blood mononuclear cells. Am J Biochem Biotechnol 2005;1:181-186.
89.
Maier E, Kurz K, Jenny M, Schennach H, Ueberall F, Fuchs D: Food preservatives sodium benzoate and propionic acid and colorant curcumin suppress Th1-type immune response in vitro. Food Chem Toxicol 2010;48:1950-1956.
90.
Wüthrich B: Food allergy, food intolerance or functional disorder? Praxis (Bern 1994) 2009;98:375-387.
91.
Bujuktiryaki B, Sahiner UM, Girgin G, Yavuz ST, Cavkatayar O, Yilmaz AE, Birben E, Tuncer A, Baydar T, Sackesen C: The role of tryptophan-kynurenine pathway in food allergy and tolerance development. Pteridines 2013;23(suppl 1):S43-S44.
92.
Peeters KA, Lamers RJ, Penninks AH, Knol EF, Bruijnzeel-Koomen CA, van Nesselrooij JH, Knulst AC: A search for biomarkers as diagnostic tools for food allergy: a pilot study in peanut-allergic patients. Int Arch Allergy Immunol 2011;155:23-30.
93.
Ellwood P, Asher MI, García-Marcos L, Williams H, Keil U, Robertson C, Nagel G; ISAAC Phase III Study Group: Do fast foods cause asthma, rhinoconjunctivitis and eczema? Global findings from the International Study of Asthma and Allergies in Childhood (ISAAC) phase three. Thorax 2013;68:351-360.
94.
Jenny M, Klieber M, Zaknun D, Schroecksnadel S, Kurz K, Ledochowski M, Schennach H, Fuchs D: In vitro testing for anti-inflammatory properties of compounds employing peripheral blood mononuclear cells freshly isolated from healthy donors. Inflamm Res 2011;60:127-135.
95.
Strasser B, Berger K, Fuchs D: Effects of a caloric restriction weight loss diet on tryptophan metabolism and inflammatory biomarkers in overweight adults. Eur J Nutr 2015;54:101-107.
96.
Wurtman RJ, Wurtman JJ: Brain serotonin, carbohydrate-craving, obesity and depression. Obes Res 1995;3(suppl 4):477S-480S.
97.
de Theije CG, Wu J, Koelink PJ, Korte- Bouws GA, Borre Y, Kas MJ, Lopes da Silva S, Korte SM, Olivier B, Garssen J, Kraneveld AD: Autistic-like behavioural and neurochemical changes in a mouse model of food allergy. Behav Brain Res 2014;261:265-274.
98.
Lyall K, van de Water J, Ashwood P, Hertz-Picciotto I: Asthma and allergies in children with autism spectrum disorders: results from the CHARGE study. Autism Res 2015;8:567-574.
99.
Arnold LE, Lofthouse N, Hurt E: Artificial food colors and attention-deficit/hyperactivity symptoms: conclusions to dye for. Neurotherapeutics 2012;9:599-609.
100.
Jutel M, Watanabe T, Akdis M, Blaser K, Akdis CA: Immune regulation by histamine. Curr Opin Immunol 2002;14:735-740.
101.
Andersson M, Greiff L, Svensson C: Allergic rhinoconjunctivitis: the role of histamine. Mediators Inflamm 1994;3:171-175.
102.
Gruber A, Murr C, Wirleitner B, Werner-Felmayer G, Fuchs D: Histamine suppresses neopterin production in the human myelomonoctoma cell line THP-1. Immunol Lett 2000;72:133-136.
103.
Naito Y, Uchiyama K, Takagi T, Yoshikawa T: Therapeutic potential of carbon monoxide (CO) for intestinal inflammation. Curr Med Chem 2012;19:70-76.
104.
Strasser B, Gostner JM, Fuchs D: Carbon monoxide exposure may underlie the increased leukaemia risk in children living next to motor highways. Eur J Epidemiol 2015;30:1329-1330.
105.
Hosick PA, Stec DE: Heme oxygenase, a novel target for the treatment of hypertension and obesity? Am J Physiol Regul Integr Comp Physiol 2012;302:R207-R214.
106.
Ristow M, Zarse K, Oberbach A, Klöting N, Birringer M, Kiehntopf M, Stumvoll M, Kahn CR, Blüher M: Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci USA 2009;106:8665-8670.
107.
Peternelj TT, Coombes JS: Antioxidant supplementation during exercise training: beneficial or detrimental? Sports Med 2011;41:1043-1069.
108.
Steinbacher P, Eckl P: Impact of oxidative stress on exercising skeletal muscle. Biomolecules 2015;5:356-377.
109.
Pedersen BK: Muscle as a secretory organ. Compr Physiol 2013;3:1337-1362.
110.
Steensberg A: The role of IL-6 in exercise-induced immune changes and metabolism. Exerc Immunol Rev 2003;9:40-47.
111.
Steensberg A, Toft AD, Bruunsgaard H, Sandmand M, Halkjaer-Kristensen J, Pedersen BK: Strenuous exercise decreases the percentage of type 1 T cells in the circulation. J Appl Physiol 2001;91:1708-1712.
112.
Walsh NP, Gleeson M, Shephard RJ, Gleeson M, Woods JA, Bishop NC, Fleshner M, Green C, Pedersen BK, Hoffman-Goetz L, Rogers CJ, Northoff H, Abbasi A, Simon P: Position statement. Part one. Immune function and exercise. Exerc Immunol Rev 2011;17:6-63.
113.
Gostner JM, Becker K, Sperner-Unterweger B, Überall F, Fuchs D, Strasser B: Role of tryptophan metabolism in mood, behavior, and cognition; in Mittal S (ed): Targeting the Broadly Pathogenic Kynurenine Pathway. Cham, Springer, 2015.
114.
Dijkstra HP, Robson-Ansley P: The prevalence and current opinion of treatment of allergic rhinitis in elite athletes. Curr Opin Allergy Clin Immunol 2011;11:103-108.
115.
Dienz O, Rincon M: The effects of IL-6 on CD4 T cell responses. Clin Immunol 2009;130:27-33.
116.
Geiger D, Schauer M, Gatterer H, Burtscher M, Fuchs D, Strasser B: Effects of exhaustive exercise on tryptophan-kynurenine metabolism in trained athletes. 12th ISEI Symposium, Cells Meet Function in Exercise Immunology, Vienna, 2015. Abstract 40:O24.
117.
Sprenger H, Jacobs C, Nain M, Gressner AM, Prinz H, Wesemann W, Gemsa D: Enhanced release of cytokines, interleukin-2 receptors, and neopterin after long-distance running. Clin Immunol Immunopathol 1992;63:188-195.
118.
Fischer CP, Hiscock NJ, Penkowa M, Basu S, Vessby B, Kallner A, Sjöberg LB, Pedersen BK: Supplementation with vitamins C and E inhibits the release of interleukin-6 from contracting human skeletal muscle. J Physiol 2004;558:633-645.
119.
Pyne DB, West NP, Cox AJ, Cripps AW: Probiotics supplementation for athletes - clinical and physiological effects. Eur J Sport Sci 2015;15:63-72.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.